Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, Soojung Hong, Sun Kyung Baek, Soon Il Lee, Moon Young Choi, In Sook Woo
Cancer Res Treat. 2023;55(1):123-135. Published online March 24, 2022
Purpose The treatment of male breast cancer (MBC) has been extrapolated from female breast cancer (FBC) because of its rarity despite their different clinicopathologic characteristics. We aimed to investigate the distribution of intrinsic subtypes based on immunohistochemistry, their clinical impact, and treatment pattern in clinical practice through a multicenter study in Korea.
Materials and Methods We retrospectively analyzed clinical data of 248 MBC patients from 18 institutions across the country from January 1995 to July 2016.
Results The median age of MBC patients was 63 years (range, 25 to 102 years). Among 148 intrinsic subtype classified patients, 61 (41.2%), 44 (29.7%), 29 (19.5%), and 14 (9.5%) were luminal A, luminal B, human epidermal growth factor receptor 2, and triple-negative breast cancer, respectively. Luminal A subtype showed trends for superior survival compared to other subtypes. Most hormone receptor-positive patients (166 patients, 82.6%) received adjuvant endocrine treatment. Five-year completion of adjuvant endocrine treatment was associated with superior disease-free survival (DFS) in patients classified with an intrinsic subtype (hazard ratio [HR], 0.15; 95% confidence interval [CI], 0.04 to 0.49; p=0.002) and in all patients (HR, 0.16; 95% CI, 0.05 to 0.54; p=0.003).
Conclusion Distribution of subtypes of MBC was similar to FBC and luminal type A was most common. Overall survival tended to be improved for luminal A subtype, although there was no statistical significance. Completion of adjuvant endocrine treatment was associated with prolonged DFS in intrinsic subtype classified patients. MBC patients tended to receive less treatment. MBC patients should receive standard treatment according to guidelines as FBC patients.
Citations
Citations to this article as recorded by
HER2 expression and pathway status in male breast cancer patients: results of an integrated analysis among 6,150 patients Boqiang Lyu, Shidi Zhao, Hui Wang, Shouping Gong, Biyuan Wang Scientific Reports.2025;[Epub] CrossRef
Clinicopathologic Features and Prognoses of Male Patients With Breast Cancer Meiling Huang, Jingjing Xiao, Changjiao Yan, Rui Ling, Ting Wang American Journal of Men's Health.2024;[Epub] CrossRef
Jieun Lee, Hyung Soon Park, Hye Sung Won, Ji Hyun Yang, Hee Yeon Lee, In Sook Woo, Kabsoo Shin, Ji Hyung Hong, Young Joon Yang, Sang Hoon Chun, Jae Ho Byun
Cancer Res Treat. 2021;53(2):409-423. Published online October 28, 2020
Purpose
Use of cyclin-dependent kinase 4/6 inhibitors improved survival outcome of hormone receptor (HR) positive metastatic breast cancer (MBC) patients, including Asian population. However, Asian real-world data of palbociclib is limited. We analyzed the real-world clinical practice patterns and outcome in HR-positive, MBC Asian patients treated with palbociclib.
Materials and Methods
Between April 2017 to November 2019, 169 HR-positive, human epidermal growth factor-2–negative MBC patients treated with letrozole or fulvestrant plus palbocilib were enrolled from eight institutions. Survival outcome (progression-free survival [PFS]), treatment response and toxicity profiles were analyzed.
Results
Median age of letrozole plus palbociclib (145 patients, 85.8%) and fulvestrant plus palbociclib (24 patients, 14.2%) was 58 and 53.5 years, with median follow-up duration of 14.63 months (range 0.2 to 33.9 months). Median PFS (mPFS) of letrozole plus palbociclib and fulvestrant plus palbociclib was 25.6 (95% confidence interval [CI], 19.1 to not reached) and 6.37 months (95% CI, 5.33 to not reached), comparable to previous phase 3 trials. In letrozole plus palbociclib arm, luminal A (hazard ratio, 2.86; 95% CI, 1.20 to 6.80; p=0.017) and patients with good performance (Eastern Cooperative Oncology Group 0-1 [hazard ratio, 3.68; 95% CI, 1.70 to 7.96]) showed better mPFS. In fulvestrant plus palbociclib group, chemotherapy naïve patients showed better mPFS (hazard ratio, 12.51, 95% CI, 1.59 to 99.17; p=0.017). The most common grade 3 or 4 adverse event was neutropenia (letrozole 86.3%, fulvestrant 88.3%).
Conclusion
To our knowledge, this is the first real-world data of palbociclib reported in Asia. Palbociclib showed comparable benefit to previous phase 3 trials in Asian patients during daily clinical practice.
Citations
Citations to this article as recorded by
Efficacy and Safety of Cyclin-Dependent Kinase 4/6 Inhibitors in Patients with Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials and Real-World Studies Hui-Chen Su, Ho-Wei Lin, Ka-Wai Tam Targeted Oncology.2025; 20(1): 71. CrossRef
Palbociclib in Older Patients with Advanced/Metastatic Breast Cancer: A Systematic Review Etienne Brain, Connie Chen, Sofia Simon, Vinay Pasupuleti, Kathleen Vieira Pfitzer, Karen A. Gelmon Targeted Oncology.2024; 19(3): 303. CrossRef
Real-world progression-free survival and overall survival of palbociclib plus endocrine therapy (ET) in Japanese patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer in the first-line or second-l Tetsuhiro Yoshinami, Shigenori E. Nagai, Masaya Hattori, Takuho Okamura, Kenichi Watanabe, Takahiro Nakayama, Hiroko Masuda, Michiko Tsuneizumi, Daisuke Takabatake, Michiko Harao, Hiroshi Yoshino, Natsuko Mori, Hiroyuki Yasojima, Chiya Oshiro, Madoka Iwas Breast Cancer.2024; 31(4): 621. CrossRef
The Effect of C-Reactive Protein/Lymphocyte Ratio (CLR) on PFS in Metastatic Breast Cancer Patients Treated with CDK4/6 Inhibitors: A Novel Biomarker Mehmet Buyukbayram, Zekeriya Hannarici, Yakup Duzkopru, Aykut Turhan, Alperen Caglar, Pınar Coban Esdur, Mehmet Bilici, Salim Tekin, Doğan Yazılıtaş Breast Cancer: Targets and Therapy.2024; Volume 16: 329. CrossRef
The treatment pattern of advanced HR-positive and HER2-negative breast cancer in central southern China: a hospital-based cross-sectional study Zhe-Yu Hu, Binliang Liu, Ning Xie, Xiaohong Yang, Liping Liu, Huawu Xiao, Jing Li, Hui Wu, Jianxiang Gao, Jun Lu, Xuming Hu, Min Cao, Zhengrong Shui, Can Tian, Quchang Ouyang BMC Cancer.2024;[Epub] CrossRef
Palbociclib in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer: A Systematic Scoping Review of Real-World Evidence from Countries Outside of Western Regions that Are Underrepresented in Clinical Trials Amit Rauthan, Ankita Jain, Manmohan Singh, Mehmet A. N. Sendur Oncology and Therapy.2024; 12(3): 395. CrossRef
Real-world comparison of palbociclib, abemaciclib, and dalpiciclib as first-line treatments for Chinese HR+/HER2−metastatic breast cancer patients: a multicenter study (YOUNGBC-28) Yifan Chen, Yizhao Xie, Die Sang, Ning Xie, Xinhua Han, Yanxia Zhao, Juanjuan Li, Jian Yue, Peng Yuan, Biyun Wang Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China Jiao Yang, Bing Zhao, Xiaoling Ling, Donghui Li, Jiuda Zhao, Yonggang Lv, Guangxi Wang, Xinlan Liu, Nanlin Li, Jin Yang BMC Cancer.2023;[Epub] CrossRef
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program Carlo Palmieri, Alison Musson, Catherine Harper-Wynne, Duncan Wheatley, Gianfilippo Bertelli, Iain R. Macpherson, Mark Nathan, Ellie McDowall, Ajay Bhojwani, Mark Verrill, Joe Eva, Colm Doody, Ruhe Chowdhury British Journal of Cancer.2023; 129(5): 852. CrossRef
Real-world effectiveness of palbociclib plus fulvestrant in advanced breast cancer: Results from a population-based cohort study Fábio Cardoso Borges, Filipa Alves da Costa, Adriana Ramos, Catarina Ramos, Catarina Bernardo, Cláudia Brito, Alexandra Mayer-da-Silva, Cláudia Furtado, Arlindo R. Ferreira, Diogo Martins-Branco, Ana Miranda, António Lourenço The Breast.2022; 62: 135. CrossRef
The Impact of Real-World Alternative Dosing Strategies of Palbociclib on Progression-Free Survival in Patients with Metastatic Breast Cancer Fulbert Fu, Jessica Kano, Julia Ma, Mera Guindy Current Oncology.2022; 29(3): 1761. CrossRef
Treatment patterns, effectiveness, and patient‐reported outcomes of palbociclib therapy in Chinese patients with advanced breast cancer: A multicenter ambispective real‐world study Lesang Shen, Jun Zhou, Yiding Chen, Jinhua Ding, Haiyan Wei, Jian Liu, Wenjie Xia, Bojian Xie, Xiaohong Xie, Xujun Li, Yuechu Dai, Guobing Zhang, Xia Qiu, Chao Li, Shanshan Sun, Wuzhen Chen, Dihe Gong, Hengyu Li, Jian Huang, Xia Jiang, Chao Ni Cancer Medicine.2022; 11(22): 4157. CrossRef
Starting dose selection of palbociclib in Chinese patients with breast cancer based on population kinetic–pharmacodynamic model of neutropenia Weizhe Jian, Junsheng Xue, Qingyu Yao, Rong Chen, Ye Yao, Mopei Wang, Tianyan Zhou Cancer Chemotherapy and Pharmacology.2022; 90(6): 489. CrossRef
Early Application of Palbociclib Plus Endocrine Therapy in HR+/HER2− Metastatic Breast Cancer: A Better Choice Based on Data From the Chinese Population Yusi Zhang, Wenlin Chen, Shuanglong Chen, Qingmo Yang, Zhong Ouyang Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Real-world Treatment Patterns and Clinical Outcomes Associated With Palbociclib Combination Therapy: A Multinational, Pooled Analysis From the Ibrance Real World Insights Study Katie Mycock, Kent A. Hanson, Gavin Taylor-Stokes, Gary Milligan, Christian Atkinson, Debanjali Mitra, Salena Preciado, Ernest H. Law Clinical Therapeutics.2022; 44(12): 1588. CrossRef
Multicentric real world evidence with palbociclib in hormone positive HER2 negative metastatic breast cancer in Indian population Chaturbhuj Agrawal, Pankaj Goyal, Amit Agarwal, Rupal Tripathi, Chandragouda Dodagoudar, Saphalta Baghmar, Archana Sharma, Ullas Batra, Vineet Talwar, Sumit Goyal, Rajeev Kumar, Dinesh Chandra Doval Scientific Reports.2021;[Epub] CrossRef
Which Clinicopathologic Parameters Suggest Primary Resistance to Palbociclib in Combination With Letrozole as the First-Line Treatment for Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer? Ji-Yeon Kim, Jung Min Oh, Yeon Hee Park, Jin Seok Ahn, Young-Hyuck Im Frontiers in Oncology.2021;[Epub] CrossRef
PTEN hamartoma tumor syndrome is a spectrum of disorders characterized by unique phenotypic features including multiple hamartomas caused by mutations of the tumor suppressor gene PTEN. Cowden syndrome and Bannayan–Riley–Ruvalcaba syndrome are representative diseases, and both have several common clinical features and differences. Because PTEN mutations are associated with an increased risk of malignancy including breast, thyroid, endometrial, and renal cancers, cancer surveillance is an important element of disease management. We report a germline mutation of the PTEN (c.723dupT, exon 7) identified in a young woman with a simultaneous occurrence of breast cancer, dermatofibrosarcoma protuberans, and follicular neoplasm. This case suggests that it is critical for clinicians to recognize the phenotypic features associated with these syndromes to accurately diagnose them and provide preventive care.
Citations
Citations to this article as recorded by
Breast Cancer with a Newly Diagnosed Variant in the PTEN Gene: A Case Report Yuka Maeda, Tatsuhiko Ikeda, Ayana Sato, Akiko Matsumoto, Hiromitsu Jinno Surgical Case Reports.2025; 11(1): n/a. CrossRef
Synchronous and metachronous thyroid cancer, breast cancer, and melanoma in a premenopausal patient with Cowden syndrome Belinda Asare, Babita Panigrahi Radiology Case Reports.2023; 18(5): 1918. CrossRef
Molecular Action of Herbal Antioxidants in Regulation of Cancer Growth: Scope for Novel Anticancer Drugs Manjula Vinayak Nutrition and Cancer.2018; 70(8): 1199. CrossRef
Ji Hyung Hong, Kyung Sun Ha, Yun Hwa Jung, Hye Sung Won, Ho Jung An, Guk Jin Lee, Donghoon Kang, Ji Chan Park, Sarah Park, Jae Ho Byun, Young Jin Suh, Jeong Soo Kim, Woo Chan Park, Sang Seol Jung, Il Young Park, Su-Mi Chung, In Sook Woo
Cancer Res Treat. 2016;48(4):1389-1398. Published online April 11, 2016
Purpose
Breast cancer treatment has progressed significantly over the past 20 years. However, knowledge regarding male breast cancer (MBC) is sparse because of its rarity. This study is an investigation of the clinicopathologic features, treatments, and clinical outcomes of MBC.
Materials and Methods
Clinical records of 59 MBC patients diagnosed during 1995-2014 from seven institutions in Korea were reviewed retrospectively.
Results
Over a 20-year period, MBC patients accounted for 0.98% among total breast cancer patients, and increased every 5 years. The median age of MBC patientswas 66 years (range, 24 to 87 years). Forty-three patients (73%) complained of a palpable breast mass initially. The median symptom duration was 5 months (range, 1 to 36 months). Mastectomy was performed in 96% of the patients. The most frequent histology was infiltrating ductal carcinoma (75%). Ninety-one percent of tumors (38/43) were estrogen receptor–positive, and 28% (11/40) showed epidermal growth factor receptor 2 (HER-2) overexpression. After curative surgery, 42% of patients (19/45) received adjuvant chemotherapy; 77% (27/35) received hormone therapy. Five out of ten patients with HER-2 overexpressing tumors did not receive adjuvant anti–HER-2 therapy, while two out of four patients with HER-2 overexpressing tumors received palliative trastuzumab for recurrent and metastatic disease. Letrozole was used for one patient in the palliative setting. The median overall survival durations were 7.2 years (range, 0.6 to 17.0 years) in patients with localized disease and 2.9 years (range, 0.6 to 4.3 years) in those with recurrent or metastatic disease.
Conclusion
Anti–HER-2 and hormonal therapy, except tamoxifen, have been underutilized in Korean MBC patients compared to female breast cancer patients. With the development of precision medicine, active treatment with targeted agents should be applied. Further investigation of the unique pathobiology of MBC is clinically warranted.
Citations
Citations to this article as recorded by
Cost-effectiveness of adjuvant endocrine treatment with tamoxifen for male breast cancer Yaping Huang, Chengjie Ke, Jiaqin Cai, Xiaoxia Wei, Maohua Chen, Hong Sun Breast Cancer.2024; 31(5): 917. CrossRef
Cáncer de mama en el varón: estudio multicéntrico en Aragón durante 27 años Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine Cirugía Española.2024; 102(10): 524. CrossRef
Observational Study of Men and Women with Breast Cancer in Terms of Overall Survival Vlad Bogdan Varzaru, Diana-Maria Anastasiu-Popov, Anca-Elena Eftenoiu, Roxana Popescu, Daliborca Cristina Vlad, Cristian Sebastian Vlad, Aurica Elisabeta Moatar, Daniela Puscasiu, Ionut Marcel Cobec Cancers.2024; 16(17): 3049. CrossRef
Male breast cancer: A multicenter study in Aragon over 27 years Olga Dobato Portoles, Daniel Aparicio Lopez, Reyes Ibañez Carreras, Elena Aguirre Ortega, Beatriz Eizaguirre Zarza, Carmen García Mur, Aurora Carrasquer Puyal, María Pilar Cebollero Benito, Laura Isabel Comín Novella, Marta Allue Cabañuz, Fernando Martine Cirugía Española (English Edition).2024; 102(10): 524. CrossRef
Male breast cancer: a 32-year retrospective analysis in radiation therapy referral center in northern Iran Mahboobeh Asgharian, Dariush Moslemi, Hossein-Ali Nikbakht, Mohammad-Ali Jahani, Ali Bijani, Hakimeh Mehdizadeh Annals of Medicine & Surgery.2024; 86(10): 5756. CrossRef
Impacts of Subtype on Clinical Feature and Outcome of Male Breast Cancer: Multicenter Study in Korea (KCSG BR16-09) Jieun Lee, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Joohyuk Sohn, Gun Min Kim, Kyung-Hee Lee, Su Hwan Kang, Kyung Hae Jung, Jae-ho Jeong, Jae Ho Byun, Su-Jin Koh, Kyoung Eun Lee, Seungtaek Lim, Hee Jun Kim, Hye Sung Won, Hyung Soon Park, Guk Jin Lee, S Cancer Research and Treatment.2023; 55(1): 123. CrossRef
Clinicopathological features and correlation analysis of male breast cancer Lei Xi, Jinxing Zhou, Yan Wu, Rong Rong Medicine.2023; 102(30): e34408. CrossRef
Characteristics of metastasis and survival between male and female breast cancer with different molecular subtypes: A population‐based observational study Wentong Fang, Yue Huang, Xu Han, Jinghui Peng, Mingjie Zheng Cancer Medicine.2022; 11(3): 764. CrossRef
Comparison of short-term surgical outcomes between men and women with breast cancer: a retrospective study using nationwide inpatient data in Japan Takaaki Konishi, Michimasa Fujiogi, Nobuaki Michihata, Kojiro Morita, Hiroki Matsui, Kiyohide Fushimi, Masahiko Tanabe, Yasuyuki Seto, Hideo Yasunaga Breast Cancer Research and Treatment.2021; 186(3): 731. CrossRef
Ulcerated Nipple Nodule, Clinicopathologic Challenge: Answer Ahmad Adel, Mona R. E. Abdel-Halim, Yosra Abdel-Galeil The American Journal of Dermatopathology.2021; 43(6): 466. CrossRef
Genetic Landscape of Male Breast Cancer Fernando Augusto Batista Campos, Etienne Rouleau, Giovana Tardin Torrezan, Dirce Maria Carraro, José Claudio Casali da Rocha, Higor Kassouf Mantovani, Leonardo Roberto da Silva, Cynthia Aparecida Bueno de Toledo Osório, Solange Moraes Sanches, Sandrine M. Cancers.2021; 13(14): 3535. CrossRef
Treatment of male breast cancer: meta-analysis of real-world evidence A. P. Lin, T.-W. Huang, K.-W. Tam British Journal of Surgery.2021; 108(9): 1034. CrossRef
Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells Ana D. Pinzón-García, Ruben Sinisterra, Maria Cortes, Fredy Mesa, Sandra Ramírez-Clavijo PeerJ.2021; 9: e12124. CrossRef
Prognostic Factors in Male Breast Cancer: A Retrospective Nationwide Study in South Korea by the Study of SMARTSHIP Group Sungmin Park, Ho Hur, Ji Sung Lee, JaeSun Yoon, Sung Mo Hur, Il Yong Chung, Jong Won Lee, Hyun Jo Youn, Se Jeong Oh, Cheol Wan Lim, Jihyoun Lee Journal of Breast Cancer.2021; 24(6): 561. CrossRef
Meme Kanseri Cerrahisi Sonrası Lenfödem ve Uçak Seyahati Aysel GÜL, Dilek AYGİN İstanbul Gelişim Üniversitesi Sağlık Bilimleri Dergisi.2021; (15): 669. CrossRef
Italian Men Tested for BRCA1/2 Mutation: Psychological Distress during 6-Month Follow-Up F. Pellini, S. Mirandola, E. Granuzzo, S. Urbani, G. Piccinni Leopardi, G. P. Pollini Journal of Oncology.2020; 2020: 1. CrossRef
Comparing the Characteristics and Outcomes of Male and Female Breast Cancer Patients in Korea: Korea Central Cancer Registry Eun-Gyeong Lee, So-Youn Jung, Myong Cheol Lim, Jiwon Lim, Han-Sung Kang, Seeyoun Lee, Jai Hong Han, Heein Jo, Young-Joo Won, Eun Sook Lee Cancer Research and Treatment.2020; 52(3): 739. CrossRef
The effect of chemotherapy on survival in patients with nonmetastatic male breast cancer: A population‐based observational study Hong Pan, Kai Zhang, Ming Wang, Lijun Ling, Shui Wang, Wenbin Zhou Cancer.2020; 126(S16): 3830. CrossRef
Adjuvant Radiation Therapy for Male Breast Cancer—A Rare Indication? Tobias Forster, Clara Köhler, Rami El Shafie, Fabian Weykamp, Laila König, Nathalie Arians, Sebastian Adeberg, Laura Michel, Katharina Smetanay, Michael Golatta, Christof Sohn, Jörg Heil, Andreas Schneeweiss, Jürgen Debus, Juliane Hörner-Rieber Cancers.2020; 12(12): 3645. CrossRef
Male Breast Cancer: Surgical and Genetic Features and a Multidisciplinary Management Strategy Francesca Pellini, Eleonora Granuzzo, Silvia Urbani, Sara Mirandola, Marina Caldana, Davide Lombardi, Elena Fiorio, Marta Mandarà, Giovanni Paolo Pollini Breast Care.2020; 15(1): 14. CrossRef
Ultrasonographic and Mammographic Findings of Male Breast Disease Su Hong Kim, Young‐Seon Kim Journal of Ultrasound in Medicine.2019; 38(1): 243. CrossRef
Pattern of care of adjuvant radiotherapy in male breast cancer patients in clinical practice: an observational study Paul Rogowski, Stephan Schönecker, Montserrat Pazos, Daniel Reitz, Michael Braun, Martin Pölcher, Claus Hanusch, Rachel Wuerstlein, Nadia Harbeck, Sven Mahner, Claus Belka, Stefanie Corradini Strahlentherapie und Onkologie.2019; 195(4): 289. CrossRef
Survival analysis for male ductal and lobular breast cancer patients with different stages Jizhao Wang, Yuchen Sun, Jingkun Qu, Huang Zuo, Xixi Zhao, Lin Liu, Jinteng Feng, Jiansheng Wang, Guangjian Zhang Future Oncology.2019; 15(2): 167. CrossRef
Clinical features of patients with male breast cancer in Shanxi province of China from 2007 to 2016 Weigang Wang, Xiaoqin Xu, Baoguo Tian, Yan Wang, Lili Du, Ting Sun, Yanchun Shi, Xianwen Zhao, Yali Jia, Yanfeng Xi, Jiexian Jing Journal of Investigative Medicine.2019; 67(3): 699. CrossRef
Metastasis pattern and prognosis of male breast cancer patients in US: a population-based study from SEER database Jun Xie, Yao-Yu Ying, Bin Xu, Yan Li, Xian Zhang, Chong Li Therapeutic Advances in Medical Oncology.2019;[Epub] CrossRef
Different Patterns of Conditional Survival of Breast Cancer Patients by Age and Histologic Types: Evidence from the Korean Nationwide Registry So-Youn Jung, Kyu-Won Jung, Johyun Ha, Young-Joo Won, Young Ae Kim, Youngmee Kwon, Sun-Young Kong, Eun Sook Lee Cancer Epidemiology, Biomarkers & Prevention.2019; 28(7): 1169. CrossRef
Diagnostic Value of Fine-Needle Aspiration in Male Breast Lesions Raza S. Hoda, Ronald N. Arpin III, Ravi V. Gottumukkala, Kevin S. Hughes, Amy Ly, Elena F. Brachtel Acta Cytologica.2019; 63(4): 319. CrossRef
The endocrinology of male breast cancer Ian S Fentiman Endocrine-Related Cancer.2018; 25(6): R365. CrossRef
Magee Equation Recurrence Score Is Associated With Distal Metastatic Risk in Male Breast Carcinomas Yanjun Hou, Harrison S Moosavi, Lai Wei, Anil V Parwani, Xiaoxian (Bill) Li, Zaibo Li American Journal of Clinical Pathology.2018; 150(6): 491. CrossRef
Axillary lymph node metastasis as the first manifestation of male occult breast cancer Xinyu Wang, Liwen Fan, Wenxing Yan, Qi Zhang, Shunchao Bao, Ying Wang, Xin Bao, Linlin Liu Medicine.2018; 97(50): e13706. CrossRef
A review of estrogen receptor/androgen receptor genomics in male breast cancer Tesa M Severson, Wilbert Zwart Endocrine-Related Cancer.2017; 24(3): R27. CrossRef
Imaging the Male Breast Shruthi Ram, Shadi Aminololama-Shakeri Current Radiology Reports.2017;[Epub] CrossRef
Mammary gland tumors in a male Cocker Spaniel Soon-Chan Kwon, Dae-Young Yoo, Minho Ko, Kwon-Young Lee, Ho-Hyun Kwak, In-Chul Park, In-Koo Hwang, Jung-Hoon Choi, Jin-Young Chung Acta Veterinaria Scandinavica.2017;[Epub] CrossRef
Male occult breast cancer with axillary lymph node metastasis as the first manifestation Ruixin Xu, Jianbin Li, Yingjie Zhang, Hongbiao Jing, Youzhe Zhu Medicine.2017; 96(51): e9312. CrossRef
Pseudocirrhosis refers to a condition that shows changes in hepatic contour that mimic cirrhosis radiographically in the absence of the typical histopathological findings of cirrhosis. This condition has been observed in patients with cancer metastatic to the liver, both in those who have undergone prior systemic chemotherapy and those who have not. Pseudocirrhosis may cause difficulty in interpretation of the response to chemotherapy and hepatic decompression and complication of portal hypertension have a negative effect on the prognosis. We report on a case of breast cancer with liver metastases that showed cirrhotic changes during disease progression. Progression of liver metastases was confirmed by F18 fluorodeoxyglucose positron emission tomography/computed tomography (PET-CT). We also performed ultrasound-guided liver biopsy and confirmed tumor infiltration with severe desmoplastic fibrosis. This case suggests the pathogenesis of pseudocirrhosis through histopathological findings and the role of PET-CT in evaluation of the response to chemotherapy in patients with pseudocirrhosis.
Citations
Citations to this article as recorded by
Pseudocirrhosis: A Case Series with Clinical and Radiographic Correlation and Review of the Literature Gal Sadlik, Redmond-Craig Anderson, Xiaomeng Lei, Steven Yong Cen, Vinay A. Duddalwar, Tse-Ling Fong Digestive Diseases and Sciences.2024; 69(3): 1004. CrossRef
Clinical characteristics and outcomes in patients with metastatic breast cancer and pseudocirrhosis: a single center retrospective cohort study Laura A. Huppert, Zak Walker, Moming Li, Mi-Ok Kim, Jennifer Callan, Danielle Brandman, Melanie Majure, Michelle E. Melisko, Hope S. Rugo, Spencer Behr, A. Jo Chien Breast Cancer Research and Treatment.2023; 197(1): 137. CrossRef
Imaging in metastatic breast cancer, CT, PET/CT, MRI, WB-DWI, CCA: review and new perspectives Dione Lother, Marie Robert, Elliot Elwood, Sam Smith, Nina Tunariu, Stephen R.D. Johnston, Marina Parton, Basrull Bhaludin, Thomas Millard, Kate Downey, Bhupinder Sharma Cancer Imaging.2023;[Epub] CrossRef
Pseudocirrhosis Due to Desmoplastic Response to Chemotherapy in Breast Cancer Liver Metastases Kazuhide Takata, Ai Mogi, Ryo Yamauchi, Satoshi Shakado, Fumihito Hirai Cureus.2022;[Epub] CrossRef
Liver Metastases: Correlation between Imaging Features and Pathomolecular Environments Kumi Ozaki, Shohei Higuchi, Hirohiko Kimura, Toshifumi Gabata RadioGraphics.2022; 42(7): 1994. CrossRef
Clinical Outcomes of Metastatic Breast Cancer in Patients Having Imaging Liver Pseudocirrhosis with or without Evident Varices Wei-Li Ma, Dwan-Ying Chang, Ching-Hung Lin, Kao-Lang Liu, Po-Chin Liang, Huang-Chun Lien, Chan-Chuan Hu, Ling-Yun Huang, Yi-Chun Yeh, Yen-Shen Lu The Oncologist.2022; 27(12): 1008. CrossRef
Pseudocirrhosis and portal hypertension in patients with metastatic cancers: a systematic review and meta-analysis Rosanna Villani, Francesca Di Cosimo, Moris Sangineto, Antonino Davide Romano, Gaetano Serviddio Scientific Reports.2022;[Epub] CrossRef
Pseudocirrhosis in Breast Cancer – Experience From an Academic Cancer Center Dharmesh Gopalakrishnan, Ain Shajihan, Andrei S. Purysko, Jame Abraham Frontiers in Oncology.2021;[Epub] CrossRef
Unveiling the unreal: Comprehensive imaging review of hepatic pseudolesions Subramaniyan Ramanathan, Vineetha Raghu, Vivek Virmani, Adnan Sheikh, Mahmoud Al Heidous, SreeHarsha Tirumani Clinical Imaging.2021; 80: 439. CrossRef
Pseudocirrhosis after chemotherapy for gastric cancer with diffuse liver metastases: A case report Tomohito Shinoda, Toshiyuki Tanahashi, Takuji Sakuratani, Masato Ota, Seito Fujibayashi, Shunya Kiriyama, Keita Matsumoto, Kazunori Yawata, Yoshiyuki Sasaki, Shinji Osada, Makoto Yamada Molecular and Clinical Oncology.2021;[Epub] CrossRef
Imaging of the chemotherapy-induced hepatic damage: Yellow liver, blue liver, and pseudocirrhosis Linda Calistri, Vieri Rastrelli, Cosimo Nardi, Davide Maraghelli, Sofia Vidali, Michele Pietragalla, Stefano Colagrande World Journal of Gastroenterology.2021; 27(46): 7866. CrossRef
Clinical features of pseudocirrhosis in metastatic breast cancer Caspian Oliai, Michael L. Douek, Caelainn Rhoane, Abhishek Bhutada, Phillip S. Ge, Bruce A. Runyon, Xiaoyan Wang, Sara A. Hurvitz Breast Cancer Research and Treatment.2019; 177(2): 409. CrossRef
Seudocirrosis en cáncer de mama metastásico Alba Hidalgo-Blanco, Maddi Aguirresarobe-Gil de San Vicente, Santi Aresti, Eduardo de Miguel, Jose Luis Cabriada-Nuno Gastroenterología y Hepatología.2018; 41(2): 111. CrossRef
Pseudocirrhosis in metastatic breast cancer Alba Hidalgo-Blanco, Maddi Aguirresarobe-Gil de San Vicente, Santi Aresti, Eduardo de Miguel, Jose Luis Cabriada-Nuno Gastroenterología y Hepatología (English Edition).2018; 41(2): 111. CrossRef
Pseudocirrhosis after chemotherapy in breast cancer, case reports Tomoyoshi Aoyagi, Kazuaki Takabe, Tamaki Tamanuki, Hisahiro Matsubara, Hiroshi Matsuzaki Breast Cancer.2018; 25(5): 614. CrossRef
Unintended Consequences of Systemic and Ablative Oncologic Therapy in the Abdomen and Pelvis Julie C. Birch, Gaurav Khatri, Lori M. Watumull, Yull E. Arriaga, John R. Leyendecker RadioGraphics.2018; 38(4): 1158. CrossRef
Transjugular Intrahepatic Portosystemic Shunt for the Treatment of Portal Hypertension-Induced Refractory Ascites Due to Metastatic Carcinomatous Liver Disease Barbara Geeroms, Gert De Hertogh, Ragna Vanslembrouck, Hans Wildiers, Frederik Nevens, Geert Maleux Journal of Vascular and Interventional Radiology.2018; 29(12): 1713. CrossRef
Delineating Extramammary Findings at Breast MR Imaging Yiming Gao, Opeyemi Ibidapo, Hildegard K. Toth, Linda Moy RadioGraphics.2017; 37(1): 10. CrossRef
Pseudocirrhosis caused by regorafenib in an advanced rectal cancer patient with multiple liver metastases Kensuke Kumamoto, Shungo Endo, Noriyuki Isohata, Azuma Nirei, Daiki Nemoto, Kenichi Utano, Takuro Saito, Kazutomo Togashi Molecular and Clinical Oncology.2017; 6(1): 63. CrossRef
Systemic treatment in breast cancer: a primer for radiologists Aya Y. Michaels, Abhishek R. Keraliya, Sree Harsha Tirumani, Atul B. Shinagare, Nikhil H. Ramaiya Insights into Imaging.2016; 7(1): 131. CrossRef
Causes of hepatic capsular retraction: a pictorial essay Gary Xia Vern Tan, Rhian Miranda, Tom Sutherland Insights into Imaging.2016; 7(6): 831. CrossRef
Pseudocirrhosis in Gastric Cancer with Diffuse Liver Metastases after a Dramatic Response to Chemotherapy Seiichiro Mitani, Shigenori Kadowaki, Hiroya Taniguchi, Hisanori Muto, Kei Muro Case Reports in Oncology.2016; 9(1): 106. CrossRef
Pseudocirrhosis: A Case Series and Literature Review Abimbola Adike, Nina Karlin, Christine Menias, Elizabeth J. Carey Case Reports in Gastroenterology.2016; 10(2): 381. CrossRef
Cancer therapy related complications in the liver, pancreas, and biliary system: an imaging perspective Danny Ngo, Jemianne Bautista Jia, Christopher S. Green, Anjalie T. Gulati, Chandana Lall Insights into Imaging.2015; 6(6): 665. CrossRef
Liposomes, modified with PTDHIV-1 peptide, containing epirubicin and celecoxib, to target vasculogenic mimicry channels in invasive breast cancer Rui-Jun Ju, Xue-Tao Li, Ji-Feng Shi, Xiu-Ying Li, Meng-Ge Sun, Fan Zeng, Jia Zhou, Lei Liu, Cheng-Xiang Zhang, Wei-Yu Zhao, Wan-Liang Lu Biomaterials.2014; 35(26): 7610. CrossRef